All In Biotech

Drug Trial Radar · NCT01114737

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria

Last checked: Nov 20, 2026Latest source record: Feb 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Aug 2010

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
May 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Conditions

  • Phenylketonuria

Interventions

  • Sapropterin dihydrochlorideDrug

    A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).

  • PlaceboDrug

    Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS) / Adult ADHD Self-Report Scale (ASRS) Total Score From Baseline to Week 13Time frame: Baseline to Week 13
  2. Number of Participants With a Score of 1 or 2 in Global Function Evaluation (CGI-I) From Baseline to Week 13.Time frame: 13 weeks

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Gainesville, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

  • Site not named

    Rochester, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Madison, Wisconsin

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Winnipeg, Manitoba, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Kingston, Ontario, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.